Clinical trial · Interventional
Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors
A Phase 1 Study Of CP- 870,893 In Combination With Paclitaxel And Carboplatin In Patients With Metastatic Solid Tumors
NCT00607048CI-TRIAL-00026643completedPhase 1Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a dose-finding study; therefore, there is no hypothesis testing
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Paclitaxel + Carboplatin + CP-870,893 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- Schedule A
- description
- Schedule A (CP-870,893 administration schedule)
- interventionNames
- Drug: Paclitaxel + Carboplatin + CP-870,893
- type
- OTHER
- label
- Schedule B
- description
- Schedule B (CP-870,893 administration schedule)
- interventionNames
- Drug: Paclitaxel + Carboplatin + CP-870,893
Primary outcomes (1)
- measure
- Number of Participants With First Cycle Dose Limiting Toxicities (DLTs)
- timeFrame
- Schedule (Sch) A Cycle 1 / Day 3 or Schedule B Cycle 1 / Day 8 up to Cycle 1 / Day 21
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with metastatic solid tumors, for whom carboplatin and paclitaxel are appropriate; * Patients \>18 years of age; * Good performance status; * Adequate bone marrow and organ function Exclusion Criteria: * Previous treatment with any other compound that targets CD40 * Current or planned concurrent treatment with any anticancer agent; * Patients who have received bone marrow transplant; * History of autoimmune disorder * History (within the previous year) of heart failure or heart attack * Cancer-associated coagulation disorders
References
Publications (2)
- DERIVEDCai S, Wei X, Li Q, Jiang Z, Li L. Smart materials in pharmacological drug development: Neutrophils and its constituents for drug delivery and consequent antitumor effects. Mol Immunol. 2025 Jul;183:18-32. doi: 10.1016/j.molimm.2025.04.010. Epub 2025 May 2. PMID 40318595
- DERIVEDVonderheide RH, Burg JM, Mick R, Trosko JA, Li D, Shaik MN, Tolcher AW, Hamid O. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology. 2013 Jan 1;2(1):e23033. doi: 10.4161/onci.23033. PMID 23483678